Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Pipeline Promise | Explore Nurix's innovative protein degradation platform, with lead candidate Bexobrutideg showing potential in treating Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma |
Financial Fortitude | Delve into Nurix's robust cash position of $609.6 million, funding operations into 2027 despite current losses, with analyst price targets ranging from $16 to $41 |
Strategic Alliances | Uncover Nurix's valuable partnerships with pharmaceutical giants Gilead, Sanofi, and Pfizer, validating its technology and expanding market reach |
Market Expansion | Learn about Nurix's planned entry into the autoimmune disease market, potentially diversifying its portfolio and opening new revenue streams |
Metrics to compare | NRIX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNRIXPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.9x | −7.2x | −0.7x | |
PEG Ratio | 1.16 | 0.10 | 0.00 | |
Price/Book | 1.9x | 0.8x | 2.6x | |
Price / LTM Sales | 8.4x | 13.6x | 3.4x | |
Upside (Analyst Target) | 208.6% | 162.2% | 37.8% | |
Fair Value Upside | Unlock | 0.0% | 5.5% | Unlock |